Skip to content
Screener

MiMedx Group MDXG Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$118.1MBeat by $11.3M
EPS$0.14Beat by $0.05
Revenue estimate$106.8M
EPS estimate$0.09

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$69.6M
EPS estimate$0.01

Financials

Q4 2025

Income statement

See full
Revenue$118.1M+27.1%
Gross profit$99.0M+30.3%
Operating income$21.1M+90.7%
Net income$15.2M+104%
EPS (diluted)$0.10+100.0%

Balance sheet

See full
Cash & equivalents$166.1M+59.1%
Total debt$22.5M-9.3%
Total equity$256.5M+32.9%
Total assets$342.7M+29.8%

Cash flow

See full
Operating cash flow$25.0M+32.9%
CapEx$285.0K+8.4%
Free cash flow$24.7M+33.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1B-29.1%
Enterprise value$859.06M-35.6%
P/E20.6×-12.7×
P/S2.4×-1.7×

Profitability

See full
Gross margin82.6%-0.2pp
Operating margin15.3%-1.6pp
Net margin11.6%-0.6pp
FCF margin17.4%-1.1pp

Returns & leverage

See full
Return on equity21.6%-3.7pp
Debt / equity0.1×0.0×
Current ratio4.3×+0.1×

Segments

By product

See full
Wound$78.7M—
Surgical$39.4M—

FAQ

When did MiMedx Group report Q4 2025 earnings?
MiMedx Group (MDXG) reported Q4 2025 earnings on February 25, 2026 after market close.
What were MiMedx Group's Q4 2025 revenue and EPS?
MiMedx Group reported revenue of $118.1M and eps of $0.14 for Q4 2025.
Did MiMedx Group beat estimates in Q4 2025?
Revenue beat the consensus estimate of $106.8M by $11.3M. EPS beat the consensus estimate of $0.09 by $0.05.
How did MiMedx Group's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 27.1% from $92.9M a year earlier and eps grew 100.0% from $0.07.
Where can I find MiMedx Group's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001376339-26-000012) and the 10-K periodic report (0001376339-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.